Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rania El Botty

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Cancers|June 1, 2019
PARP Inhibition Increases the Response to Chemotherapy in Uveal MelanomaLeanne de Koning, Didier Decaudin, Rania El Botty, et al.
Theranostics|February 12, 2020
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenograftsFlorence Coussy, Marion Lavigne, Leanne de Koning, et al.
Oncotarget|April 23, 2021
High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLCElodie Montaudon, Rania El Botty, Sophie Vacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenograftsPaul Cottu, Ivan Bièche, Franck Assayag, et al.
Science Translational Medicine|February 28, 2024
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER<sup>+</sup> breast cancerMarina Bacci, Nicla Lorito, Alfredo Smiriglia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast CancersElisabetta Marangoni, Cécile Laurent, Florence Coussy, et al.
Nature Communications|July 14, 2023
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancersRania El-Botty, Ludivine Morriset, Elodie Montaudon, et al.
International Journal of Cancer|March 13, 2019
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancerFlorence Coussy, Leanne de Koning, Marion Lavigne, et al.
Science Translational Medicine|February 21, 2020
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancersFlorence Coussy, Rania El-Botty, Sophie Château-Joubert, et al.
Nature Communications|April 7, 2023
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancersPetra Ter Brugge, Sarah C Moser, Ivan Bièche, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cancers|June 1, 2019
PARP Inhibition Increases the Response to Chemotherapy in Uveal MelanomaLeanne de Koning, Didier Decaudin, Rania El Botty, et al.
Theranostics|February 12, 2020
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenograftsFlorence Coussy, Marion Lavigne, Leanne de Koning, et al.
Oncotarget|April 23, 2021
High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLCElodie Montaudon, Rania El Botty, Sophie Vacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenograftsPaul Cottu, Ivan Bièche, Franck Assayag, et al.
Science Translational Medicine|February 28, 2024
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER<sup>+</sup> breast cancerMarina Bacci, Nicla Lorito, Alfredo Smiriglia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast CancersElisabetta Marangoni, Cécile Laurent, Florence Coussy, et al.
Nature Communications|July 14, 2023
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancersRania El-Botty, Ludivine Morriset, Elodie Montaudon, et al.
International Journal of Cancer|March 13, 2019
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancerFlorence Coussy, Leanne de Koning, Marion Lavigne, et al.
Science Translational Medicine|February 21, 2020
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancersFlorence Coussy, Rania El-Botty, Sophie Château-Joubert, et al.
Nature Communications|April 7, 2023
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancersPetra Ter Brugge, Sarah C Moser, Ivan Bièche, et al.
Pageof 4